As of today (12th Aug 2020) the summary on https://hcqtrial.com/ of all known worldwide HCQ/CQ trials states:

Many countries either adopted or declined early treatment with HCQ, forming a large country-randomized controlled trial with 2.0 billion people in the treatment group and 663 million in the control group. As of August 12, 2020, an average of 42.0/million in the treatment group have died, and 447.8/million in the control group, relative risk 0.094. After adjustments, treatment and control deaths become 87.2/million and 646.2/million, relative risk 0.13. Confounding factors affect this estimate, including varying degrees of spread between countries. Accounting for predicted changes in spread, we estimate a relative risk of 0.21. The treatment group has a 78.7% lower death rate. We examined diabetes, obesity, hypertension, life expectancy, population density, urbanization, testing level, and intervention level, which do not account for the effect observed.

The full paper can be read at: https://hcqtrial.com/.

You may or may not have seen this previous post, which links to a partner site to the above and that now lists over 71 studies on HCQ/CQ and CV19 along with a simple statistical summary of findings.